Tagraxofusp
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018, and after a second review, in the EU in January 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Wikipage redirect
primaryTopic
Tagraxofusp
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018, and after a second review, in the EU in January 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
has abstract
Tagraxofusp, sold under the br ...... karyotic elongation factor 2).
@en
alternative name
Elzonris
@en
CAS number
2055491-00-2
DrugBank
FDA UNII code
8ZHS5657EH
KEGG
MedlinePlus
Link from a Wikipage to an external page
Wikipage page ID
59,696,846
page length (characters) of wiki page
Wikipage revision ID
1,020,954,112
Link from a Wikipage to another Wikipage
ATC prefix
L01
@en
ATC suffix
XX67
@en
CAS number
DailyMedID
Tagraxofusp
@en
DrugBank
DB14731
@en
elimination half-life
KEGG
D11358
@en
legal EU
Rx-only
@en
legal US
Rx-only
@en
MedlinePlus
a619022
@en
metabolism
Proteases
@en
routes of administration
synonyms
DT388-IL3, SL-401, tagraxofusp-erzs
@en
tradename
Elzonris
@en
wikiPageUsesTemplate
comment
Tagraxofusp, sold under the br ...... e a first-in-class medication.
@en
label
Tagraxofusp
@en